INTRODUCTION: Pro-inflammatory cytokines, such as interleukin (IL)-6, tumour necrosis factor (TNF)α, and monocyte chemoattractant protein (MCP)-1, are often elevated in individuals after acute pancreatitis but what determines their levels is poorly understood. Gut hormones have emerged as possible modulators of inflammatory response. The aim was to investigate the associations between pro-inflammatory cytokines and a comprehensive panel of gut hormones after an episode of acute pancreatitis. MATERIALS AND METHODS: Fasting blood samples were collected to measure cytokines (IL-6, TNFα, and MCP-1) and gut hormones (cholecystokinin, gastric inhibitory peptide (GIP), ghrelin, glicentin, glucagon-like peptide-1, oxyntomodulin, peptide YY, secretin, and vasoactive intestinal peptide). A series of linear regression analyses was conducted and four statistical models were used to adjust for patient- and pancreatitis-related covariates. RESULTS: A total of 83 individuals were recruited. GIP and peptide YY were significantly (p < 0.001) associated with IL-6, TNFα, MCP-1, consistently in all the four models. Every 1 ng/mL change in GIP resulted in a 16.2, 3.2, and 50.8% increase in IL-6, TNFα, and MCP-1, respectively, in the most adjusted model. Every 1 ng/mL change in peptide YY resulted in a 7.0, 2.4, and 32.1% increase in IL-6, TNFα, and MCP-1, respectively, in the most adjusted model. GIP independently contributed 29.0-36.5% and peptide YY - 17.4-48.9% to circulating levels of the studied pro-inflammatory cytokines. The other seven studied gut hormones did not show consistently significant associations with pro-inflammatory cytokines. CONCLUSIONS: GIP and peptide YY appear to be involved in perpetuation of subclinical inflammation following an episode of acute pancreatitis, which is known to play an important role in the pathogenesis of blood glucose derangements. These findings advance the understanding of mechanisms underlying diabetes of the exocrine pancreas and have translational implications.
INTRODUCTION: Pro-inflammatory cytokines, such as interleukin (IL)-6, tumour necrosis factor (TNF)α, and monocyte chemoattractant protein (MCP)-1, are often elevated in individuals after acute pancreatitis but what determines their levels is poorly understood. Gut hormones have emerged as possible modulators of inflammatory response. The aim was to investigate the associations between pro-inflammatory cytokines and a comprehensive panel of gut hormones after an episode of acute pancreatitis. MATERIALS AND METHODS: Fasting blood samples were collected to measure cytokines (IL-6, TNFα, and MCP-1) and gut hormones (cholecystokinin, gastric inhibitory peptide (GIP), ghrelin, glicentin, glucagon-like peptide-1, oxyntomodulin, peptide YY, secretin, and vasoactive intestinal peptide). A series of linear regression analyses was conducted and four statistical models were used to adjust for patient- and pancreatitis-related covariates. RESULTS: A total of 83 individuals were recruited. GIP and peptide YY were significantly (p < 0.001) associated with IL-6, TNFα, MCP-1, consistently in all the four models. Every 1 ng/mL change in GIP resulted in a 16.2, 3.2, and 50.8% increase in IL-6, TNFα, and MCP-1, respectively, in the most adjusted model. Every 1 ng/mL change in peptide YY resulted in a 7.0, 2.4, and 32.1% increase in IL-6, TNFα, and MCP-1, respectively, in the most adjusted model. GIP independently contributed 29.0-36.5% and peptide YY - 17.4-48.9% to circulating levels of the studied pro-inflammatory cytokines. The other seven studied gut hormones did not show consistently significant associations with pro-inflammatory cytokines. CONCLUSIONS:GIP and peptide YY appear to be involved in perpetuation of subclinical inflammation following an episode of acute pancreatitis, which is known to play an important role in the pathogenesis of blood glucose derangements. These findings advance the understanding of mechanisms underlying diabetes of the exocrine pancreas and have translational implications.
Authors: Ruma G Singh; Harry D Yoon; Sally D Poppitt; Lindsay D Plank; Maxim S Petrov Journal: Diabetes Metab Res Rev Date: 2017-09-06 Impact factor: 4.876
Authors: Sakina H Bharmal; Sayali A Pendharkar; Ruma G Singh; Mark O Goodarzi; Stephen J Pandol; Maxim S Petrov Journal: Pancreatology Date: 2017-09-20 Impact factor: 3.996
Authors: Stephanie L M Das; Primal P Singh; Anthony R J Phillips; Rinki Murphy; John A Windsor; Maxim S Petrov Journal: Gut Date: 2013-08-08 Impact factor: 23.059
Authors: E Maraví Poma; C Laplaza Santos; B Gorraiz López; E Albeniz Arbizu; F Zubia Olascoaga; M S Petrov; F A Morales; M Aizcorbe Garralda; M Casi Villaroya; J A Sánchez-Izquierdo Riera; V López Camps; E Regidor Sanz; M Loinaz Bordonabe; J L do Pico Journal: Med Intensiva Date: 2012-05-06 Impact factor: 2.491
Authors: E Ferrannini; E Muscelli; A Natali; R Gabriel; A Mitrakou; A Flyvbjerg; A Golay; K Hojlund Journal: Diabetologia Date: 2007-09-11 Impact factor: 10.122
Authors: Corinna Lebherz; Florian Kahles; Katja Piotrowski; Michael Vogeser; Ann Christina Foldenauer; Kirsten Nassau; Erich Kilger; Nikolaus Marx; Klaus G Parhofer; Michael Lehrke Journal: Cardiovasc Diabetol Date: 2016-02-03 Impact factor: 9.951